Bellerophon Therapeutics Inc., of Warren, N.J., reported the closing of its public offering of 10 million shares at 70 cents each for gross proceeds of $7 million. In addition, the underwriter has also been granted a 45-day option to purchase up to an additional 1.5 million shares. The company said it intends to use the net proceeds to fund working capital and other general corporate purposes.